Short answer
Biohaven Ltd. (BHVN) filed an 8-K current report with the SEC on August 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Exclusive worldwide Kv7 license to SKBP, centered on Phase 2/3 epilepsy drug opakalim, subject to antitrust clearance and closing conditions.
Biohaven Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive worldwide Kv7 license to SKBP, centered on Phase 2/3 epilepsy drug opakalim, subject to antitrust clearance and closing conditions
- $400M upfront: $350M at closing and $50M one year later, plus up to $150M development and regulatory milestones
- Tiered royalties: mid-teens to low twenties on U.S. sales, mid-single digits internationally, with additional licensed-product royalties
- SKBP assumes up to $245M legacy MIPA milestones and mid-single-digit worldwide sales royalties, separate from new obligations
- Biohaven retains development responsibilities for RISE 2, RISE 3 and NDA preparation, with SKBP reimbursing specified costs and funding development-plan expenses
Item 7.01 · Regulation FD Disclosure
- Biohaven announced a transaction under its License Agreement, including assumption of certain obligations to Knopp
- Exhibit 99.1 contains the press release and transaction details investors should review
- Disclosure date: August 26, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biohaven Ltd. 8-K filings
Get the next BHVN 8-K as it lands
Follow BHVN for push alerts, or ask the research agent what this filing means.